JP2015522264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522264A5 JP2015522264A5 JP2015519009A JP2015519009A JP2015522264A5 JP 2015522264 A5 JP2015522264 A5 JP 2015522264A5 JP 2015519009 A JP2015519009 A JP 2015519009A JP 2015519009 A JP2015519009 A JP 2015519009A JP 2015522264 A5 JP2015522264 A5 JP 2015522264A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- group
- seq
- nos
- virological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 37
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 208000015114 central nervous system disease Diseases 0.000 claims description 4
- 208000026278 immune system disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 238000000099 in vitro assay Methods 0.000 claims description 2
- 238000005462 in vivo assay Methods 0.000 claims description 2
- 108020004707 nucleic acids Chemical group 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 108090000623 proteins and genes Chemical group 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 150000003384 small molecules Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000002265 prevention Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664210P | 2012-06-26 | 2012-06-26 | |
| US61/664,210 | 2012-06-26 | ||
| PCT/EP2013/063088 WO2014001229A2 (en) | 2012-06-26 | 2013-06-24 | Cell penetrating peptides & methods of identifying cell penetrating peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015522264A JP2015522264A (ja) | 2015-08-06 |
| JP2015522264A5 true JP2015522264A5 (enExample) | 2016-08-12 |
Family
ID=48672631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519009A Ceased JP2015522264A (ja) | 2012-06-26 | 2013-06-24 | 細胞透過性ペプチドおよび細胞透過性ペプチドを同定する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150183827A1 (enExample) |
| EP (1) | EP2864348A2 (enExample) |
| JP (1) | JP2015522264A (enExample) |
| KR (1) | KR20150032265A (enExample) |
| CN (1) | CN104428310A (enExample) |
| BR (1) | BR112014027239A2 (enExample) |
| CA (1) | CA2869283A1 (enExample) |
| HK (1) | HK1205749A1 (enExample) |
| MX (1) | MX2014014464A (enExample) |
| RU (1) | RU2015102027A (enExample) |
| WO (1) | WO2014001229A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10144767B2 (en) * | 2016-08-18 | 2018-12-04 | Board Of Regents Of The University Of Nebraska | Anti-microbial peptides and coatings |
| WO2018156892A1 (en) | 2017-02-23 | 2018-08-30 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
| EP3634978A1 (en) | 2017-06-07 | 2020-04-15 | Adrx, Inc. | Tau aggregation inhibitors |
| EP3668886A2 (en) | 2017-08-18 | 2020-06-24 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| CN108070025B (zh) * | 2017-10-24 | 2019-11-19 | 中山大学附属口腔医院 | 一种细胞穿透肽和细胞穿透肽复合物及二者的应用 |
| EP3556767A1 (en) * | 2018-04-18 | 2019-10-23 | Universidade De Santiago De Compostela | Cell penetrating peptides |
| JP7523358B2 (ja) | 2018-06-13 | 2024-07-26 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | ムスカリン受容体ｍ３に対して阻害活性を有するペプチド |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812980D0 (en) * | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| JP7489319B2 (ja) * | 2018-09-26 | 2024-05-23 | 株式会社カネカ | 細胞膜透過性ペプチド |
| EP3890783A1 (en) | 2018-12-07 | 2021-10-13 | Oxford University Innovation Limited | Linkers |
| JP7644429B2 (ja) * | 2019-02-19 | 2025-03-12 | ヨーロピアン モレキュラー バイオロジー ラボラトリー | 細胞透過性トランスポザーゼ |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003022992A2 (en) * | 2001-09-06 | 2003-03-20 | Schering Corporation | Mammalian genes; related reagents |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| JP5067624B2 (ja) * | 2006-02-07 | 2012-11-07 | 日本電気株式会社 | Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター |
| WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| EP2080519A1 (en) * | 2008-01-15 | 2009-07-22 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Peptides having binding affinity to an antibody which recognizes an epitope on an alpha1 loop 2 or beta 2 loop 1 of an adrenoreceptor |
| JP2010085108A (ja) * | 2008-09-29 | 2010-04-15 | Nano Factory:Kk | 生体光イメージング用プローブ |
| SG186347A1 (en) * | 2010-06-14 | 2013-01-30 | Hoffmann La Roche | Cell-penetrating peptides and uses therof |
-
2013
- 2013-06-24 MX MX2014014464A patent/MX2014014464A/es unknown
- 2013-06-24 CA CA2869283A patent/CA2869283A1/en not_active Abandoned
- 2013-06-24 US US14/410,930 patent/US20150183827A1/en not_active Abandoned
- 2013-06-24 CN CN201380033264.0A patent/CN104428310A/zh active Pending
- 2013-06-24 HK HK15106419.3A patent/HK1205749A1/xx unknown
- 2013-06-24 KR KR1020147036389A patent/KR20150032265A/ko not_active Withdrawn
- 2013-06-24 EP EP13730888.8A patent/EP2864348A2/en not_active Ceased
- 2013-06-24 RU RU2015102027A patent/RU2015102027A/ru not_active Application Discontinuation
- 2013-06-24 JP JP2015519009A patent/JP2015522264A/ja not_active Ceased
- 2013-06-24 BR BR112014027239A patent/BR112014027239A2/pt not_active IP Right Cessation
- 2013-06-24 WO PCT/EP2013/063088 patent/WO2014001229A2/en not_active Ceased
-
2017
- 2017-06-16 US US15/625,219 patent/US20180094030A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522264A5 (enExample) | ||
| RU2015102027A (ru) | Проникающие в клетку пептиды и способы идентификации проникающих в клетку пептидов | |
| JP2024116287A (ja) | 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法 | |
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| TN2012000393A1 (en) | Agonist dr5 binding polypeptides | |
| JP2018510881A5 (enExample) | ||
| WO2010115998A3 (en) | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders | |
| US11130790B2 (en) | Cell penetrating peptides that inhibit IRF5 nuclear localization | |
| PH12014501642A1 (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
| WO2011157713A4 (en) | Cell-penetrating peptides and uses therof | |
| JP2010166916A5 (enExample) | ||
| HRP20220250T1 (hr) | Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe | |
| JP2008538183A5 (enExample) | ||
| JP2015510393A5 (enExample) | ||
| JP2012529293A5 (enExample) | ||
| JP2013515745A5 (enExample) | ||
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| JP2019534884A5 (enExample) | ||
| RU2014125496A (ru) | Комбинированная терапия для лечения нарушений слуха и равновесия | |
| JP2013504603A5 (enExample) | ||
| HRP20160385T1 (hr) | Pripravci za prevenciju i liječenje neurodegenerativnih bolesti | |
| JP2021502977A (ja) | 神経学的状態、がん、細菌性感染症又はウイルス性感染症の治療及び／又は予防のためのｓｒｓｆ３作用剤の使用 | |
| JP2017517561A5 (enExample) | ||
| US20160095897A1 (en) | Par-4 antagonists for use in the treatment or prevention of influenza virus type a infections |